Abstract:Because of improved survival of cancer patients, more patients irradiated for brain metastases develop intracerebral recurrences requiring subsequent courses of radiotherapy. Five studies focused on reirradiation with whole-brain radiation therapy (WBRT) after initial WBRT for brain metastases. Following the second WBRT course, improvement of clinical symptoms was found in 31-68% of patients. Rates of neurotoxicity, such as encephalopathy or cognitive decline, were reported in two studies (1.4% and 32%). In another study, severe or unexpected adverse events were not observed. Survival following the second WBRT course was generally poor, with median survival times of 2.9-4.1 months. The survival prognosis of patients receiving two courses of WBRT can be estimated by a scoring tool considering five prognostic factors. Three studies investigated reirradiation with single-fraction stereotactic radiosurgery (SF-SRS) following primary WBRT. One-year local control rates were 74-91%, and median survival times ranged between 7.8 and 14 months. Rates of radiation necrosis (RN) after reirradiation were 0-6%. Seven studies were considered that investigated re-treatment with SF-SRS or fractionated stereotactic radiation therapy (FSRT) following initial SF-SRS or FSRT. One-year local control rates were 60-88%, and the median survival times ranged between 8.3 and 25 months. During follow-up after reirradiation, rates of overall (asymptomatic or symptomatic) RN ranged between 12.5% and 30.4%. Symptomatic RN occurred in 4.3% to 23.9% of cases (patients or lesions). The risk of RN associated with symptoms and/or requiring surgery or corticosteroids appears lower after reirradiation with FSRT when compared to SF-SRS. Other potential risk factors of RN include the volume of overlap of normal tissue receiving 12 Gy at the first course and 18 Gy at the second course of SF-SRS, maximum doses ≥40 Gy of the first or the second SF-SRS courses, V12 Gy >9 cm3 of the second course, initial treatment with SF-SRS, volume of normal brain receiving 5 Gy during reirradiation with FSRT, and systemic treatment. Cumulative EQD2 ≤100-120 Gy2 to brain, <100 Gy2 to brainstem, and <75 Gy2 to chiasm and optic nerves may be considered safe. Since most studies were retrospective in nature, prospective trials are required to better define safety and efficacy of reirradiation for recurrent or progressive brain metastases.

Application of re-course stereotactic radiotherapy

Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review

Reirradiation with Stereotactic Body Radiotherapy for Primary or Secondary Lung Malignancies: Tumor Control Probability and Safety Analyses

Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases

The study of re-irradiation for head and neck cancer

Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours

Thoracic Reirradiation with Stereotactic Body Radiation Therapy (SBRT) for recurrent advanced non-small cell lung cancer (NSCLC)

Precision Stereotactic Radiotherapy for Spinal Tumors: Mechanism, Efficacy, and Issues

Precision Stereotactic Radiotherapy for Spinal Tumors: Mechanism, Efficacy, and Issues.

Reirradiation of metastases of the central nervous system: part 1—brain metastasis

An Overview of the Development of Stereotactic Body Radiation Therapy

Advances of radiobiology in stereotactic body radiation therapy

P20.01 Stereotactic Body Radiation Therapy for Residual Primary Lesions after First Line Treatment for Advanced Non-Small Cell Lung Cancer

Pelvic recurrence after definitive surgery for locally advanced rectal cancer: a retrospective investigation of implications for precision radiotherapy field design.

Advancements of radiotherapy for recurrent head and neck cancer in modern era

Research progress on brachytherapy for recurrent cervical cancer

Application of stereotactic body radiation therapy to cancer liver metastasis

Retreatment of Craniopharyngioma After External Radiotherapy and Intracapsular Radiochemotherapy

Stereotactic radiosurgery for recurrent pediatric brain tumors: clinical outcomes and toxicity

Stereotactic Body Radiation Therapy for Patients with Recurrent Pancreatic Adenocarcinoma at the Abdominal Lymph Nodes or Postoperative Stump Including Pancreatic Stump and Other Stump

Correction: Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study